NCT00431951View on ClinicalTrials.gov

Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Healthy
Interventions
DRUG

ST-246

250 mg, 400 mg or 800 mg capsules given once daily for 21 days

DRUG

Placebo

Capsules to match experimental drug

Trial Locations (1)

32809

Orlando Clinical Research, Orlando

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

SIGA Technologies

INDUSTRY

NCT00431951 - Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers | Biotech Hunter | Biotech Hunter